ClinConnect ClinConnect Logo
Search / Trial NCT04194216

Antibiotic Prophylaxis in Rhinoplasty

Launched by STANFORD UNIVERSITY · Dec 9, 2019

Trial Information

Current as of July 23, 2025

Enrolling by invitation

Keywords

Rhinoplasty Antibiotic Prophylaxis

ClinConnect Summary

The study will consist of 2 treatment arms:

Treatment arm A: Intra-operative single intravenous(iv) dose of "cephalexin" 2 g or "clindamycin" 900 mg.

Treatment arm B: Intra-operative single intravenous(iv) dose of "cephalexin" 2 g or "clindamycin" 900 mg and postoperative oral dose of "cephalexin" 250mg every 4 hours or "clindamycin" 150mg every 6 hours, for a duration of three days.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Adult patients (aged 18years and older)
  • Exclusion Criteria:
  • Prior rhinoplasty
  • Any exogenous (non-nasal) grafts/implants
  • Immune deficiency (DM, meds, other)
  • History of radiotherapy to nose

About Stanford University

Stanford University is a prestigious academic institution renowned for its cutting-edge research and innovation in healthcare and medicine. As a clinical trial sponsor, Stanford leverages its extensive resources, including a collaborative network of world-class researchers and state-of-the-art facilities, to advance medical knowledge and improve patient care. The university is committed to conducting rigorous, ethical research that adheres to the highest standards of scientific integrity, fostering an environment where groundbreaking discoveries can translate into effective clinical applications. Through its clinical trials, Stanford aims to address critical health challenges and contribute to the development of novel therapies and treatment strategies.

Locations

Stanford, California, United States

Patients applied

0 patients applied

Trial Officials

Sam P Most, MD

Principal Investigator

Stanford Facial Plastic and Reconstructive Surgery

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials